Revive Therapeutics Ltd (RVVTF)

[Life is great]

Earlier this year, Revive Therapeutics enjoyed an explosive catalyst to the coronavirus. A life sciences company, Revive announced that it was exploring the drug Bucillamine as a potential treatment for Covid-19. The move to focus on a treatment as opposed to a vaccine likely contributed to the astounding momentum of RVVTF stock.

For one thing, a vaccine won’t help those who already have Covid-19. More importantly, we just don’t know how long it will take for a vaccine to hit the market, let alone administer it to billions across the globe. Plus, many folks have apprehensions about taking a vaccine. And don’t get me started about the implications of the government forcing everyone to take it.
Thus, Revive’s proposal strikes a healthy balance. However, RVVTF stock is more than just a play on the coronavirus. In February of this year, Revive announced the acquisition of Psilocin Pharma, which specializes in psychedelic-based therapies.